Search

The Catering Service Industry (CSI) experienced profound impacts due to the COVID-19 pandemic. However, the long-term and multi-timepoint analysis using big data remained limited, influencing governmental decision-making. We applied Kernel Density Estimation, Shannon Diversity Index, and the Geographic detector to explore the spatial heterogeneity and determinants of the CSI in Beijing during the pandemic, with monthly granularity. The temporal-spatial dynamics of the CSI presented a "W"-shaped trend from 2018 to 2023, with pivotal shifts aligning with key pandemic stages. Spatial characteristics exhibited heterogeneity, with greater stability in the city center and more pronounced shifts in peripheral urban zones. Districts facing intricate outbreaks showed lower catering income, and Chinese eateries exhibited heightened resilience compared to others. The CSI displayed strong interconnections with living service sectors. Development in each district was influenced by economic level, population distribution, service facilities convenience, and the risk of the COVID-19 pandemic. Dominant factors included total retail sales of consumer goods, permanent population, average Baidu Heat Index, density of transportation and catering service facilities, infection cases and the consecutive days with confirmed cases existing. Consequently, we suggested seizing post-pandemic recovery as an avenue to unlock the CSI's substantial potential, ushering a fresh phase of growth. [ABSTRACT FROM AUTHOR]

Purpose: Iodine 123 labeled meta-iodobenzylguanidine ([123I]MIBG) scan with SPECT/CT imaging is one of the most commonly used imaging modalities in the evaluation of neuroblastoma. [18F]-meta-fluorobenzylguanidine ([18F]MFBG) is a novel positron emission tomography (PET) tracer which was reported to have a similar biodistribution to [123I]MIBG. However, the experience of using [18F]MFBG PET/CT in the evaluation of patients with neuroblastoma is limited. This preliminary investigation aims to assess the efficacy of [18F]MFBG PET/CT in the evaluation of neuroblastomas in comparison to [123I]MIBG scans with SPECT/CT. Materials and methods: In this prospective, single-center study, 40 participants (mean age 6.0 ± 3.7 years) with history of neuroblastoma were enrolled. All children underwent both [123I]MIBG SPECT/CT and [18F]MFBG PET/CT studies. The number of lesions and the Curie scores revealed by each imaging method were recorded. Results: Six patients had negative findings on both [123I]MIBG and [18F]MFBG studies. Four of the 34 patients (11.8%) were negative on [123I]MIBG but positive on [18F]MFBG, while 30 patients were positive on both [123I]MIBG and [18F]MFBG studies. In these 34 patients, [18F]MFBG PET/CT identified 784 lesions while [123I]MIBG SPECT/CT detected 532 lesions (p < 0.001). The Curie scores obtained from [18F]MFBG PET/CT (11.32 ± 8.18, range 1-27) were statistically higher (p < 0.001) than those from [123I]MIBG SPECT/CT (7.74 ± 7.52, range 0-26). 30 of 34 patients (88.2%) with active disease on imaging had higher Curie scores based on the [18F]MFBG study than on the [123I]MIBG imaging. Conclusion: [18F]MFBG PET/CT shows higher lesion detection rate than [123I]MIBG SPECT/CT in the evaluation of pediatric patients with neuroblastoma. Clinical trial registration: Clinicaltrials.gov: NCT05069220 (Registered: 25 September 2021, retrospectively registered); Institute Review Board of Peking Union Medical College Hospital: ZS-2514 [ABSTRACT FROM AUTHOR]